> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Federal Register Notices 7/3 to 7/10
- URL: https://www.fdaweb.com/federal-register-notices-7-3-to-7-10/
- Published: 2023-07-10T12:00:00.000Z
- Updated: 2026-09-14T18:42:43.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5154834

Here the health product-related *Federal Register* notices published by the agency during ***FDA Webview***’s 7/3-10 annual break for Independence Day:

**July 10**

*Federal Register* notice: FDA has submitted to OMB an information collection extension entitled “Human Cells, Tissues, and Cellular and Tissue-Based Products — 21 CFR Part 1271.” The collection supports the agency’s regulations covering such product requirements for registering and listing. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2023-07-10/pdf/2023-14467.pdf?ref=fdaweb.com).

*Federal Register* notice: FDA has announced an 8/1 Medical Imaging Drugs Advisory Committee meeting. Panel members are scheduled to discuss dosimetry data needed to support the initial clinical study in an original IND application for certain new positron emission tomography drugs. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2023-07-10/pdf/2023-14460.pdf?ref=fdaweb.com).

**July 3**

*Federal Register* notice: FDA has announced a 9/13 Cardiovascular and Renal Drugs Advisory Committee meeting. Panel members are scheduled to discuss an Alnylam Pharmaceuticals supplemental NDA for Onpattro (patisiran) lipid complex for injection for the proposed treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2023-07-03/pdf/2023-14037.pdf?ref=fdaweb.com). 

*\[Editor’s note: There were no FDA-published Federal Register notices on 7/4, 7/5, 7/6 and 7/7.\]*